QURE (uniQure) Total Company Value-to-Revenue Ratio

uniqure.com (QURE) - corporate logo

uniQure N.V. (QURE) has cemented its reputation as a scientific leader through its pioneer status in treating Hemophilia B. The EV/Sales ratio, which stands at 65190.38, illustrates how this authority correlates with transparent pipeline management and cost control. Minimal geopolitical influence and the humanitarian profile of its developments provide the issuer with a stable growth outlook across global markets.

Company Value to Revenue: uniQure Corp (QURE) for 11/23/2025 - 11/20/2026

uniqure.com - analytical breakdowns and key metrics (QURE)

- share price and expert price forecast:
- cash and cash flow indicators:
Fundamental company valuation:uniqure.com, QURE
Product sample of uniQure N.V.

This indicator determines the market value of the business, adjusted for net debt, relative to generated revenue. The price-to-sales multiple trend allows for an assessment of the premium paid for the asset. The calculation combines market capitalization and debt load, dividing the resulting sum by revenue. For uniQure N.V. (QURE), this metric reflects investment expectations for gene therapy. High values here are driven by scientific potential that remains independent of market cycles.

Competitor analysis

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple